Last reviewed · How we verify
NCT07229924: CognitiveBS
Evaluation of Cognitive Improvement After Bariatric Surgery Using a Virtual Reality Program and the Neuropsi Neuropsychological Battery
NA trial testing Bariatric Surgery in Obesity (Disorder) in 42 participants. Currently enrolling.
25 June 2025
Quick facts
| Lead sponsor | Hospital General de México Dr. Eduardo Liceaga |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 42 |
| Start date | 25 June 2024 |
| Primary completion | 25 June 2025 |
| Estimated completion | 1 March 2026 |
| Sites | 2 locations across Canada, Mexico |
Drugs / interventions tested
- Bariatric Surgery
Conditions studied
- Obesity (Disorder) — all drugs for Obesity (Disorder) →
- Obesity and Obesity-related Medical Conditions — all drugs for Obesity and Obesity-related Medical Conditions →
Sponsor
Hospital General de México Dr. Eduardo Liceaga
Who can join
Adults 18 to 65, any sex, with Obesity (Disorder) or Obesity and Obesity-related Medical Conditions. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Background: Obesity is a chronic, systemic, and multifactorial disease affecting populations worldwide, with projections indicating a 50% increase by 2035. It is linked to higher risks of cognitive decline, brain atrophy, and neurodegenerative diseases like Alzheimer's. Bariatric surgery has shown benefits in reducing fat and systemic inflammation, which may improve cognitive function. However, the factors predicting such improvements remain unclear. Objective: To evaluate the effect of bariatric surgery on cognitive performance using virtual reality (Neurotracker) and the Neuropsi neuropsychological battery. Methods: This prospective quasi-experimental study will include patients with morbid obesity who are candidates for bariatric surgery. Cognitive performance will be evaluated using the Neurotracker virtual reality tool and the Neuropsi neuropsychological battery. Participants will complete Neurotracker sessions three times weekly for two weeks before surgery, and again at 3- and 6-months post-surgery. The Neuropsi assessment will be conducted once prior to surgery and repeated at 6 months afterward. Statistical analyses will compare cognitive performance before and after the surgical intervention. Expected Outcomes: The study aims to identify measurable improvements in cognitive function after weight loss from bariatric surgery, evaluated through both traditional neuropsychological tests and immersive virtual reality tools. These results could improve understanding of the cognitive benefits of surgical obesity treatment and the factors that predict these outcomes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07229924
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Bariatric Surgery
Trials testing the same drug.
- NCT06541977 — A New Model of Exercise Referral Scheme Before and After Bariatric Surgery for People With Obesity · NA · not yet recruiting
- NCT06803888 — Bariatric Surgery vs. Semaglutide vs. Tirzepatide · Phase 4 · recruiting
- NCT07172997 — Non-Invasive MASLD Diagnosis & T2D Remission Biomarkers · active not recruiting
- NCT06556459 — Psychological and Psychopathological Characteristics of Patients With Obesity Candidates for Bariatric Surgery · not yet recruiting
- NCT06538948 — Direct Measurement of Ingestive Behaviour in Relation to Sex Differences and Gastrointestinal Hormone Levels in Patients · recruiting
Other recruiting trials for Obesity (Disorder)
Currently open trials in the same condition.
- NCT07313384 — Dietary Insights and Nutrition Experiences in Adults on GLP-1 Therapy - A Study on Diet Quality Changes in Adults on GLP · recruiting
- NCT07227051 — Optimizing Self-Monitoring Feedback Delivery for the Treatment of Overweight and Obesity · NA · recruiting
- NCT07448090 — Real-World Registry Study of Integrated Traditional Chinese and Western Medicine for Obesity · recruiting
- NCT07268508 — Impact of a Pro-diversity Gut Microbiota Diet After a Bariatric Surgery on Gut Microbiota, Eating Behaviour and Sensory · NA · recruiting
- NCT07126587 — Healthy Living Anson Study · NA · recruiting
Other Hospital General de México Dr. Eduardo Liceaga trials
Trials by the same sponsor.
- NCT06786364 — Types of Photoplethysmographic Waves in Adult Patients with Septic Shock · recruiting
- NCT06622538 — Orotracheal Intubation with the ORION Videolaryngoscope Versus the King Vision Videolaryngoscope in Adult Patients: ORIO · NA · completed
- NCT06318104 — Efficacy and Safety of a Triple Eradication Scheme for Helicobacter Pylori Based on Tegoprazan vs Esomeprazole · Phase 4 · unknown
- NCT04475991 — Safety and Efficacy of Maraviroc and/or Favipiravir With Standard Therapy in Severe COVID-19 Adults · Phase 2 · terminated
- NCT04512508 — Anal Injury Screening for High Risk HPV · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07229924 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital General de México Dr. Eduardo Liceaga
- Last refreshed: 17 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07229924.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing